As of 2026-09-20, the EV/EBITDA ratio of Sorrento Therapeutics Inc (SRNE) is -0.21. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRNE's latest enterprise value is 73.06 mil USD. SRNE's TTM EBITDA according to its financial statements is -340.66 mil USD. Dividing these 2 quantities gives us the above SRNE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.5x - 21.5x | 15.9x |
| Forward P/E multiples | 12.8x - 18.5x | 15.6x |
| Fair Price | (2.82) - (3.86) | (3.29) |
| Upside | -704171.1% - -964737.3% | -822095.3% |
| Date | EV/EBITDA |
| 2026-09-16 | -0.21 |
| 2026-09-15 | -0.21 |
| 2026-09-14 | -0.21 |
| 2026-09-11 | -0.21 |
| 2026-09-10 | -0.21 |
| 2026-09-09 | -0.21 |
| 2026-09-08 | -0.21 |
| 2026-09-04 | -0.22 |
| 2026-09-03 | -0.22 |
| 2026-09-02 | -0.22 |
| 2026-09-01 | -0.22 |
| 2026-08-31 | -0.21 |
| 2026-08-28 | -0.21 |
| 2026-08-27 | -0.21 |
| 2026-08-26 | -0.22 |
| 2026-08-25 | -0.22 |
| 2026-08-24 | -0.22 |
| 2026-08-21 | -0.22 |
| 2026-08-20 | -0.22 |
| 2026-08-19 | -0.22 |
| 2026-08-18 | -0.22 |
| 2026-08-17 | -0.22 |
| 2026-08-14 | -0.22 |
| 2026-08-13 | -0.22 |
| 2026-08-12 | -0.21 |
| 2026-08-11 | -0.21 |
| 2026-08-10 | -0.21 |
| 2026-08-07 | -0.21 |
| 2026-08-06 | -0.21 |
| 2026-08-05 | -0.22 |
| 2026-08-04 | -0.22 |
| 2026-08-03 | -0.21 |
| 2026-07-31 | -0.21 |
| 2026-07-30 | -0.21 |
| 2026-07-29 | -0.21 |
| 2026-07-28 | -0.21 |
| 2026-07-27 | -0.21 |
| 2026-07-24 | -0.21 |
| 2026-07-23 | -0.22 |
| 2026-07-22 | -0.22 |
| 2026-07-21 | -0.22 |
| 2026-07-20 | -0.22 |
| 2026-07-17 | -0.22 |
| 2026-07-16 | -0.22 |
| 2026-07-15 | -0.22 |
| 2026-07-14 | -0.22 |
| 2026-07-13 | -0.22 |
| 2026-07-10 | -0.22 |
| 2026-07-09 | -0.22 |
| 2026-07-08 | -0.22 |